These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1091 related articles for article (PubMed ID: 33140515)
1. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Lim B; Song J; Ibrahim NK; Koenig KB; Chavez-MacGregor M; Ensor JE; Gomez JS; Krishnamurthy S; Caudle AS; Shaitelman SF; Whitman GJ; Valero V Oncologist; 2021 Feb; 26(2):e230-e240. PubMed ID: 33140515 [TBL] [Abstract][Full Text] [Related]
2. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig G; Royce M; McCall LM; Ewer MS; Hunt KK; Lancet Oncol; 2013 Dec; 14(13):1317-25. PubMed ID: 24239210 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. Tokunaga S; Takashima T; Kashiwagi S; Noda S; Kawajiri H; Tokumoto M; Nishimura S; Nishimori T; Ikeda K; Ogawa Y; Mizuyama Y; Sunami T; Tezuka K; Yamagata S; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M Anticancer Res; 2019 Apr; 39(4):2053-2059. PubMed ID: 30952749 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148 [TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study. Narui K; Miura D; Hasegawa Y; Tachibana A; Horiguchi J; Hayashi M; Miyashita M; Kubota T; Suzuki M; Yamada K; Yamada A; Akazawa K; Kohno N; Ishikawa T Clin Breast Cancer; 2022 Dec; 22(8):e881-e891. PubMed ID: 36151017 [TBL] [Abstract][Full Text] [Related]
6. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Robidoux A; Buzdar AU; Quinaux E; Jacobs S; Rastogi P; Fourchotte V; Younan RJ; Pajon ER; Shalaby IA; Desai AM; Fehrenbacher L; Geyer CE; Mamounas EP; Wolmark N Clin Breast Cancer; 2010 Feb; 10(1):81-6. PubMed ID: 20133263 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer. Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379 [TBL] [Abstract][Full Text] [Related]
8. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial. Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181 [TBL] [Abstract][Full Text] [Related]
9. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Del Mastro L; Poggio F; Blondeaux E; De Placido S; Giuliano M; Forestieri V; De Laurentiis M; Gravina A; Bisagni G; Rimanti A; Turletti A; Nisticò C; Vaccaro A; Cognetti F; Fabi A; Gasparro S; Garrone O; Alicicco MG; Urracci Y; Mansutti M; Poletti P; Correale P; Bighin C; Puglisi F; Montemurro F; Colantuoni G; Lambertini M; Boni L; Lancet Oncol; 2022 Dec; 23(12):1571-1582. PubMed ID: 36370716 [TBL] [Abstract][Full Text] [Related]
10. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2 Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191 [TBL] [Abstract][Full Text] [Related]
11. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634 [TBL] [Abstract][Full Text] [Related]
12. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS; Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer. Nakamura S; Ando M; Masuda N; Aogi K; Ino H; Iwata H; Tokuda Y; Yamamoto N; Kasai H; Takeuchi M; Tsuda H; Akiyama F; Kurosumi M; Fujiwara Y Clin Breast Cancer; 2012 Feb; 12(1):49-56. PubMed ID: 22154118 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
15. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300 [TBL] [Abstract][Full Text] [Related]
16. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526 [TBL] [Abstract][Full Text] [Related]
17. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig GW; Royce ME; Hunt KK JAMA Oncol; 2019 Jan; 5(1):45-50. PubMed ID: 30193295 [TBL] [Abstract][Full Text] [Related]
18. Feasibility Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (150 mg/m Kojima Y; Kawamoto H; Nishikawa T; Hayami R; Shimo A; Haku E; Akiyama K; Tsugawa K Clin Breast Cancer; 2018 Oct; 18(5):374-379. PubMed ID: 29452759 [TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459 [TBL] [Abstract][Full Text] [Related]
20. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer. Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]